医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Vitruvias Therapeutics Inc., Licenses Potassium Chloride ER ANDA (10 and 20 mEq) Capsules to Be Manufactured at Bora Pharmaceutical’s New Zhunan Facility in Taiwan

2018年12月05日 PM08:00
このエントリーをはてなブックマークに追加


 

AUBURN, Ala. & TAIPEI, Taiwan

Vitruvias Therapeutics Inc., an Auburn, Alabama-based finished-dose generic drug development company, has agreed to license an approved Potassium Chloride Extended release ANDA. The product will be manufactured by Bora Pharmaceutical’s Zhunan site, which was recently acquired from Impax.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181205005200/en/

Carl Whatley, Chairman and CEO of Vitruvias stated that “as a 40-year veteran if this industry, I have toured many manufacturing facilities, and Bora’s Zhunan facility is one of the best I have ever seen. Being a relatively new facility and having the responsibility and FDA approval for the manufacturing of Impax’s U.S. products, its size, quality systems, state-of-the-art high volume equipment and highly responsive personnel make it a logical choice for our portfolio of technically complex oral solids.”

“Bora Pharmaceuticals is honored to be in business with Vitruvias. Their experienced management team has a stellar track record of successful product launches and their pipeline of products has positioned the company for explosive growth. We are excited to show our large-scale solvent capabilities and to give Vitruvias a high-quality competitive product in the market. We look forward to a long-term relationship with them,” says Bobby Sheng, Chairman and CEO of Bora Pharmaceuticals.

Potassium Chloride Extended Release tablets are used to prevent or to treat low blood levels of potassium (hypokalemia). Current annual sales1 of all forms of Potassium Chloride Extended Release tablets totaled approximately 1.66 billion tablets through September 2018.

This is the first contract manufacturing agreement between Vitruvias and Bora.

About Vitruvias

Vitruvias is a generic pharmaceutical company which utilizes domestic and international partnerships to develop, manufacture, and market technically difficult generic products. Founded in 2013, the company’s primarily focus is on products in the generic sterile injectable market, semi-solid market, and selected high-value oral solids. The Company received its first approval in September 2017, and anticipates additional approvals in late 2018 and early 2019. www.vitruvias.com

About Bora

Bora Pharmaceuticals (TSE: 6472) is a publicly traded, Taiwan based, pharmaceutical company that covers the entire pharmaceutical value chain from CDMO services to marketing and sales. Bora has a solid financial foundation, experienced management team, and long-standing partnerships with best in class multinational Pharmaceutical companies. Bora, and its subsidiaries produce, market, and sell products ranging from Generics, Consumer Health, and In-Patent Branded Drugs. In addition, Bora Pharmaceuticals’ U.S. FDA, PIC/S and GMP certified plants provides large scale outsourced R&D and contract manufacturing services to over 16 countries worldwide. https://cdmo.bora-corp.com

1 Source: IQVIA, National Sales Perspectives, Sept 2018

View source version on businesswire.com: https://www.businesswire.com/news/home/20181205005200/en/

CONTACT

Roger Graben, PhD
President
Vitruvias Therapeutics Inc.
Phone
+1 (334) 329-5601
roger@vitruvias.com

Bobby
Sheng
Chairman & CEO
Bora Pharmaceuticals
Phone +886
2-2790 1555
Bobby.sheng@bora-corp.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024